Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Carboplatin (Primary) ; Cetuximab (Primary) ; Fluorouracil (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms GORTEC-ELANFIT
- 23 Oct 2018 Planned End Date changed from 1 Dec 2019 to 1 Aug 2021.
- 23 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2019.